Acolyte and Berthold form Marketing Alliance
News Jun 05, 2006
Berthold Technologies GmbH & Co. KG will support distribution of Acolyte’s BacLite® RapiTECT range of enumeration assays in Europe and the United States.
The BacLite® range currently includes BacLite® RapiTECT GRAM NEGATIVE (GN)™ for the rapid detection and enumeration of gram negative bacterial cells and BacLite® RapiTECT Mammalian (M)™ for the rapid enumeration of mammalian cells.
The BacLite® RapiTECT assay range uses adenylate kinase (AK) as a highly sensitive marker of viable cells.
Previous research has demonstrated that AK enhances the sensitivity of cell enumeration and acts as a reliable reporter of viable cells than ATP bioluminescence.
Unlike ATP, AK is present at relatively constant levels in viable cells and can be used to count cells at very low levels due to the ADP»ATP amplification process.
This AK rapid® technology is up to 100 times more sensitive than standard ATP bioluminescence and up to 1 million times more sensitive than optical measurements.
Applications for the BacLite® RapiTECT GRAM NEGATIVE (GN)™ assay include bacterial growth and inhibition studies, anti-microbial research and a range of other microbiological, bio-processing and pharmacological applications.
The BacLite® RapiTECT MAMMALIAN (M)™ assay can be used in drug discovery, bioengineering, bio-processing and genetic research as well as many areas of academic and institution based research.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE